Tenax Therapeutics has been issued a U.S. patent covering oral levosimendan, also known as TNX-103, for the treatment of pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). The patent (U.S. Patent No. 11,701,355) is expected to provide intellectual property protection for TNX-103 through December 2040.
Babies born preterm, or before 37 weeks of pregnancy, were shown to have a higher risk of developing pulmonary hypertension (PH), primarily between the ages of 1 and 3, according to a study in Sweden. Moreover, that risk was seen to increase as the length of the pregnancy decreased,…
A one-time surgical procedure called pulmonary artery denervation or PADN was linked to a reduced risk of clinical worsening in the long term for people with combined pre- and post-capillary pulmonary hypertension (CpcPH). That’s according to three-year data from a clinical trial involving CpcPH patients who underwent the procedure.
People with precapillary pulmonary hypertension (PH) and a poorly working right ventricle may benefit from ranolazine, which is used for chest pain caused by heart disease. Data from a Phase 4 study where PH patients took ranolazine for about six months showed better right heart function and more sugar…
Exposure to air pollutants significantly increased the risk of pulmonary hypertension (PH), according to a U.K. population study that included almost 500,000 people. Previous or current smoking increased PH risk and mortality even further, suggesting a synergistic relationship, the researchers noted. The large-scale study, “Dynamic association…
Tailored educational videos on healthy eating coupled with online instruction led to helpful dietary changes in a group of pulmonary arterial hypertension (PAH) patients and the likelihood of a better quality of life, a pilot trial in the Netherlands reports. People assigned to one of two diet plans continued…
Zymedi is collaborating with the National Heart, Lung, and Blood Institute (NHLBI) to advance the development of its first-in-class pulmonary arterial hypertension (PAH) treatment candidate ZMA001. The South Korea-based company and the NHLBI, part of the National Institutes of Health, have signed a clinical Cooperative Research and Development…
Note: This story was corrected July 10, 2023, to reflect that attendees at the European Cardiac and Respiratory Societies discussed the therapy Tyvaso with regard to the 2022 pulmonary hypertension diagnosis and treatment guidelines. Pulmonary hypertension (PH) experts are calling for care protocols to expedite patient referrals to…
Algorithm Sciences, which is developing PulmoProst to treat pulmonary arterial hypertension (PAH), has acquired all assets of Flownix Medical, including the Prometra II pump that would deliver the potential therapy. PulmoProst is an infusion formulation of iloprost, a synthetic version of naturally occurring prostacyclin, a substance that…
Liquidia has licensed the rights in North America to L606, a novel inhaled formulation of treprostinil that’s being tested in trials of people with pulmonary arterial hypertension (PAH) or pulmonary hypertension associated with interstitial lung disease (PH-ILD). “L606 is the perfect life-cycle complement to our pipeline and…
Janssen Pharmaceuticals has submitted an application in Europe asking regulatory authorities to approve the company’s combination therapy of macitentan and tadalafil — developed as a single tablet — for pulmonary arterial hypertension (PAH). The filing comes less than a month after Janssen submitted a similar application seeking approval…
Pregnant women with mild pulmonary hypertension (PH) show a significantly lower risk of maternal and fetal complications than those with moderate-to-severe PH, according to a study from China. “For patients with mild pulmonary hypertension and good cardiac function, continued pregnancy or even delivery should be considered under multidisciplinary monitoring,”…
Get regular updates to your inbox.